Member Info for Greend100

It’s not lost on the Chris’s, the dilutive impact of placings, given their holdings.
In their shoes, I’d ideally get a couple of positive RNS’s out in the next month (there’s enough going on you would think) to get away from current prices, see the SP back into the teens, then get a less dilutive placing out the way next quarter (don’t think they’d need a lot) and then have a clear run upwards…blue sky on this one after that imv

I think it’s very positive in that you can see the new direction and scale of opportunity, pregnancy saliva test market is huge in its own right, and the Lloyds opportunity in Ireland (and soon UK) is large. Don’t know if scope for Boots / Supermarkets, have asked the question.
Not sure how market will react as no forward figures yet (understandably) and I think it’s clear they’ll need a placing this FY as the cash won’t last into FY24 when they expect breakeven - guess is that we’ll see a little bounce and then settle down again. Potential for multiples from current SP, just need to get past that cash question first imv …

I think you’ve just highlighted why they wouldn’t get acquired yet imho :-)

I could see it happening in time but not until the SP is well north of current position. An acquisition would typically be 25-50% above SP, you get the odd one significantly higher like Amryt, but that was for a developing drug portfolio (107% above closing SP).

This just takes 3-4 decent contract wins and it’s back to 40-50p in short order. The sector is starting to look more positive…prove profitability and investment will come back…Hvivo’s just done 100% increase in 6 weeks…and that’s from a starting c £70mn MC.

Abdx are starting from £7mn and with a small free float.

They just need to show they can win decent sized contracts (they can’t really guide on contract margins until a trading update as would only make sense to do that with aggregated financial data)…

I did wonder if this is Martin Lang… given the investment level, felt like it had to be someone who understood the science and working in the field with BioNTech…could be wrong…

https://www.linkedin.com/in/martin-lang-292728b2?originalSubdomain=de

Remove the gap before Vox - nothing of great interest just flagging coverage…

https://www. **********.co.uk/articles/trader-s-cafe-with-zak-mir-the-week-in-small-caps-february-12-3a5d55f

The buying has seemed different this week from previous, no pull backs till today and that was short lived…see what Monday brings…when folk are buying £500k’s worth at 19.5 and 19.75, seems a stronger motivation than just referencing a Liberum forecast of 25p target (Finncap were at 35p (originally 44p)) but each II will have their own take on it.
Personally see this hitting 30p by the end of the quarter…just imv

This is a Berkshire Hathaway report released yesterday - was posted on another share chat by a well researched poster - it’s targeted at finance markets so sits behind paywall to read beyond contents pages - but highlights opportunity in the diagnostic markets etc…Angle plc cited as one of the main opportunities…

https://markets.financialcontent.com/stocks/article/bizwire-2023-2-8-global-companion-diagnostic-markets-report-2023-the-future-of-diagnostics-by-application-technology-and-funding-with-customized-forecastinganalysis-and-executive-and-consultant-guides-researchandmarketscom

Great find…
Only 128 companies on that list and looks global (or at least US/Europe)…they’re in good company…
You do have to wonder who’s still selling with the developing momentum here…

I’ve always shared the view it will be a larger CRO which acquires Hvivo eventually, the likes of Icon at £5bn MC.

However a bit of digging by someone else invested here suggested links to a US pharma player that makes GSK a minnow in comparison.
Just to run that scenario if a large pharma did buy Hvivo…
1) They might have 20-30 programmes that have ph2 requirements, and maybe 4-5 of these a year would fall under the CHIM agent portfolio Hvivo has, remainder based on other clinical needs - saves you money and time to market…(proven)
2) Critically, prevents your peers e.g. Pfizer, Sanofi etc…using the route which slows their development path giving competitive advantage,
3) Exclusivity to CV19 Chim agent…

If it isn’t one, wouldn’t rule out a collaboration of 2-3 pharma companies doing it as a joint play…

Likely to be an FDA regulator issue but assume that could be overcome with certain barriers between parent company and Hvivo.

Unlikely granted, but not implausible…

Actually it’s just a distribution agreement for UK/Ireland - ignore my previous message.

Surely this should have been RNS’d if they’re manufacturing them for Salistick…any thoughts?

Was wondering if this is our Martin Lang…

https://www.investegate.co.uk/frontpoint-offshore/rns/re--directorate/200403051612222215W/

https://www.sec.gov/Archives/edgar/data/1756575/000131586319000875/xslFormDX01/primary_doc.xml

Thanks CC…every day’s a school day :-)

Just a general question - see if anyone had a view…
Get the TR-1 2 weeks ago has M Lang had gone from 0% to 7.5%,
However, 7.5% to 8%, why issue a TR-1, didn’t think you needed to until 10%?

I think that’s helped by II’s mopping up some retail sales, but more critically new investors seeing value at this sp (whether off their own backs or guided by The Times etc…)

Feels more like a carrot to for when a sale gets done.
Think most folk would expect Hvivo to be acquired this FY, so 3 year targets become arbitrary.
Agree could have more bullish targets and start from current position, but suspect Hvivo will be 25p+ in the next 3 months given likelihood of hitting £60m+ this FY, UK II investment, potential APAC investment as profile grows there etc…
Think site expansion (or not) could be telling - if they need more space at £65ish mn, would need to be doing something later this FY, will see whether they look to do so…

Would be intrigued if abdx are talking to these guys, both York based…
Worth a listen
https://m.youtube.com/watch?v=RH09hd7oZWo

https:// www. youtube.com/watch?v=rFEF0_0RHoI
Remove the spaces…CF on Redcloud.

Good sleuthing Muck… seems to be a bit more positive momentum here…

Clearly you can sell quicker, but you are then either hitting the share price or need some news flow to generate volume.
(may be that he had no intention of selling further and was just de-risking a little…don’t need to be binary calls)